Review Article


2018, 11(6): 2932–2950


Nanomaterial-assisted sensitization of oncotherapy

Yufei Wang1,2, Juan Liu3, Xiaowei Ma1,2 (*), and Xing-Jie Liang1,2 (*)

View Author's information

1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China
2University of Chinese Academy of Sciences, Beijing 100049, China
3Tissue Engineering Lab, Beijing Institute of Transfusion Medicine, Beijing 100850, China

Keywords: nanomaterial, oncotherapy, sensitization of oncotherapy, multidrug resistance
Full article PDF
Cite this article(Endnote)
Share this article

views: 349

Citations: 0

  • Abstract
  • References
ABSTRACT Globally, cancer is growing at an alarming pace, which calls for development of more efficient cancer treatments. Conventional chemotherapy and radiotherapy have become crucial first-line clinical treatments for cancer. However, along with their wide usage, limited therapeutic effects, severe adverse reactions, unaffordable costs, and complicated operations lead to failures of these treatments. Moreover, the emergence of multidrug resistance inhibits the longtime usage of chemotherapeutics. One of the major causes of treatment failure is the insufficient sensitivity of cancer cells to therapeutic drugs or treatments. With the rigorous development of nanotechnology, tailored nanoparticles can efficiently sensitize malignant cells by inducing intracellular structural and functional changes, which could affect vital intracellular processes such as metabolism, signal conduction, proliferation, cell death as well as intracellular drug delivery. Here, we review recent advances in nanomaterial-assisted sensitization of oncotherapy, and challenges and strategies in the development of nanomedical approaches.
Related Article
Cite this article

Nanomaterial-assisted sensitization of oncotherapy. Nano Res. 2018, 11(6): 2932–2950

Download citation